Advances of Drug Resistance Marker of Gemcitabine for Non-small Cell Lung Cancer

Abstract

With the development of pharmacogenomics and pharmacogenetics, personal therapy based on genes has become one of the most effective ways to enhance chemotherapeutic effect on non-small cell lung cancer (NSCLC) patients. Much attention has been paid to validate the predictive biomarkers of chemotherapy in order to guide chemotherapy and enhance effect in general. Gemcitabine is one of the common agents treating NSCLC recently. This review is mainly about the recent reports on potential biomarkers of Gemcitabine in tailored therapy of NSCLC.

Keywords

• Lung neoplasms
• Gemcitabine
• Human equilibrative nucleoside transporter1
• Ribonucleotide reductase M
• Deoxicytidine kinase